• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新西兰毛利族与非毛利族前列腺癌男性患者的生存差异。

Survival disparities between Māori and non-Māori men with prostate cancer in New Zealand.

作者信息

Obertová Zuzana, Scott Nina, Brown Charis, Stewart Alistair, Lawrenson Ross

机构信息

Waikato Clinical School, University of Auckland, Hamilton, New Zealand.

出版信息

BJU Int. 2015 Apr;115 Suppl 5:24-30. doi: 10.1111/bju.12900.

DOI:10.1111/bju.12900
PMID:25124231
Abstract

OBJECTIVE

To examine temporal trends and current survival differences between Māori and non-Māori men with prostate cancer in New Zealand (NZ).

PATIENTS AND METHODS

A cohort of 37,529 men aged ≥ 40 years diagnosed with prostate cancer between 1996 and 2010 was identified from the New Zealand Cancer Registry and followed until 25 May 2011. Cause of death was obtained from the Mortality Collection by data linkage. Survival for Māori compared with non-Māori men was estimated using the Kaplan-Meier method, and Cox proportional hazard regression models, adjusted for age, year of diagnosis, socioeconomic deprivation and rural/urban residence.

RESULTS

The probability of surviving was significantly lower for Māori compared with non-Māori men at 1, 5 and 10 years after diagnosis. Māori men were more likely to die from any cause [adjusted hazard ratio (aHR) 1.84, 95% confidence interval (CI) 1.72-1.97] and from prostate cancer (aHR 1.94, 95% CI 1.76- 2.14). The aHR of prostate cancer death for Māori men diagnosed with regional extent was 2.62-fold (95% CI 1.60-4.31) compared with non-Māori men. The survival gap between Māori and non-Māori men has not changed throughout the study period.

CONCLUSION

Māori men had significantly poorer survival than non-Māori, particularly when diagnosed with regional prostate cancer. Despite improvements in survival for all men diagnosed after 2000, the survival gap between Māori and non-Māori men has not been reduced with time. Differences in prostate cancer detection and management, partly driven by higher socioeconomic deprivation in Māori men, were identified as the most likely contributors to ethnic survival disparities in NZ.

摘要

目的

研究新西兰(NZ)患前列腺癌的毛利族和非毛利族男性的时间趋势及当前的生存差异。

患者与方法

从新西兰癌症登记处识别出1996年至2010年间确诊患前列腺癌的37529名年龄≥40岁的男性队列,并随访至2011年5月25日。通过数据链接从死亡率数据库获取死亡原因。使用Kaplan-Meier方法以及经年龄、诊断年份、社会经济剥夺程度和城乡居住情况调整的Cox比例风险回归模型,估计毛利族男性与非毛利族男性的生存率。

结果

确诊后1年、5年和10年,毛利族男性的生存概率显著低于非毛利族男性。毛利族男性更易死于任何原因[调整后风险比(aHR)1.84,95%置信区间(CI)1.72 - 1.97]以及死于前列腺癌(aHR 1.94,95% CI 1.76 - 2.14)。与非毛利族男性相比,诊断为局部扩散的毛利族男性前列腺癌死亡的aHR为2.62倍(95% CI 1.60 - 4.31)。在整个研究期间,毛利族和非毛利族男性之间的生存差距未发生变化。

结论

毛利族男性的生存率显著低于非毛利族男性,尤其是在诊断为局部前列腺癌时。尽管2000年后确诊的所有男性的生存率有所提高,但毛利族和非毛利族男性之间的生存差距并未随时间缩小。前列腺癌检测和治疗方面的差异,部分由毛利族男性较高的社会经济剥夺程度所驱动,被确定为新西兰种族生存差异的最可能原因。

相似文献

1
Survival disparities between Māori and non-Māori men with prostate cancer in New Zealand.新西兰毛利族与非毛利族前列腺癌男性患者的生存差异。
BJU Int. 2015 Apr;115 Suppl 5:24-30. doi: 10.1111/bju.12900.
2
Differences in survival between Māori and New Zealand Europeans with prostate cancer.患有前列腺癌的毛利人与新西兰欧洲人在生存率上的差异。
Eur J Cancer Care (Engl). 2016 Mar;25(2):262-8. doi: 10.1111/ecc.12468.
3
Treatment modalities for Māori and New Zealand European men with localised prostate cancer.针对患有局限性前列腺癌的毛利族和新西兰欧洲族男性的治疗方式。
Int J Clin Oncol. 2015 Aug;20(4):814-20. doi: 10.1007/s10147-014-0781-4. Epub 2015 Jan 6.
4
Inequalities between Māori and non-Māori men with prostate cancer in Aotearoa New Zealand.新西兰奥特亚罗瓦地区患前列腺癌的毛利男性与非毛利男性之间的不平等现象。
N Z Med J. 2020 Sep 4;133(1521):69-76.
5
Prostate cancer outcomes disparities: Population survival analysis in an ethnically diverse nation.前列腺癌结局差异:一个种族多元化国家的人群生存分析
Urol Oncol. 2021 Jun;39(6):367.e19-367.e26. doi: 10.1016/j.urolonc.2021.02.023. Epub 2021 Apr 12.
6
Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.新西兰毛利族和非毛利族男性的前列腺特异性抗原(PSA)筛查及后续调查。
BMC Fam Pract. 2014 Aug 26;15:145. doi: 10.1186/1471-2296-15-145.
7
The impact of non-structured PSA testing on prostate cancer-specific mortality on New Zealand Māori men.新西兰毛利男性中,非结构化 PSA 检测对前列腺癌特异性死亡率的影响。
World J Urol. 2024 Oct 3;42(1):558. doi: 10.1007/s00345-024-05260-2.
8
Ethnic Disparities for Survival and Mortality in New Zealand Patients With Head and Neck Cancer.新西兰头颈部癌症患者的生存和死亡率的种族差异。
JAMA Netw Open. 2024 Jun 3;7(6):e2413004. doi: 10.1001/jamanetworkopen.2024.13004.
9
Ethnic differences in prostate cancer survival in New Zealand: a national study.新西兰前列腺癌生存率的种族差异:一项全国性研究。
Cancer Causes Control. 2008 Nov;19(9):993-9. doi: 10.1007/s10552-008-9166-1. Epub 2008 May 14.
10
Racial/ethnic disparities in survival among men diagnosed with prostate cancer in Texas.德克萨斯州被诊断患有前列腺癌的男性患者中,生存状况存在种族/民族差异。
Cancer. 2011 Mar 1;117(5):1080-8. doi: 10.1002/cncr.25671. Epub 2010 Nov 8.

引用本文的文献

1
Quality of life and supportive care needs in prostate cancer: the impact of treatment received and care service utilization among Māori and non-Māori patients in New Zealand.前列腺癌患者的生活质量与支持性护理需求:新西兰毛利族和非毛利族患者所接受治疗及护理服务利用情况的影响
Support Care Cancer. 2025 May 20;33(6):483. doi: 10.1007/s00520-025-09521-7.
2
The Landscape of Supportive Care Needs Among Prostate Cancer Patients in New Zealand: A Cross-Ethnic Analysis.新西兰前列腺癌患者支持性护理需求状况:一项跨种族分析。
Psychooncology. 2025 Feb;34(2):e70110. doi: 10.1002/pon.70110.
3
Physical Health Views Among Individuals Experiencing Mental Illness: A Mixed-Methods Study of Self-Reported Health and Contributing Factors.
患有精神疾病个体的身体健康观:一项关于自我报告健康状况及影响因素的混合方法研究
Int J Ment Health Nurs. 2025 Feb;34(1):e13489. doi: 10.1111/inm.13489.
4
Comparing cancer incidence, stage at diagnosis and outcomes of First Nations and all other Manitobans: a retrospective analysis.比较第一民族和所有其他马尼托巴省居民的癌症发病率、诊断时的分期和结局:一项回顾性分析。
BMC Cancer. 2019 Nov 6;19(1):1055. doi: 10.1186/s12885-019-6296-7.
5
Ethnic inequalities in cancer incidence and mortality: census-linked cohort studies with 87 million years of person-time follow-up.癌症发病率和死亡率中的种族不平等:与人口普查相关的队列研究,随访人时达8700万年。
BMC Cancer. 2016 Sep 26;16(1):755. doi: 10.1186/s12885-016-2781-4.
6
Uric acid: a modulator of prostate cells and activin sensitivity.尿酸:前列腺细胞和激活素敏感性的调节剂。
Mol Cell Biochem. 2016 Mar;414(1-2):187-99. doi: 10.1007/s11010-016-2671-8. Epub 2016 Feb 24.
7
Treatment modalities for Māori and New Zealand European men with localised prostate cancer.针对患有局限性前列腺癌的毛利族和新西兰欧洲族男性的治疗方式。
Int J Clin Oncol. 2015 Aug;20(4):814-20. doi: 10.1007/s10147-014-0781-4. Epub 2015 Jan 6.
8
Updates in the care and management of prostate cancer: highlights from the 2013 prostate cancer world congress, august 6-10, 2013, melbourne, australia.前列腺癌护理与管理的最新进展:2013年8月6日至10日于澳大利亚墨尔本召开的2013年前列腺癌世界大会要点
Rev Urol. 2013;15(4):185-7.
9
The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer.新西兰前列腺癌男性中雄激素剥夺疗法(ADT)和化疗药物的使用。
J Cancer. 2014 Feb 14;5(3):214-20. doi: 10.7150/jca.8152. eCollection 2014.